Transgender individuals experience unique health disparities but are the subject of little focused health research. This manuscript reviews current literature on transgender medical and mental health outcomes and proposes research priorities to address knowledge gaps.
INTRODUCTION
Transgender individuals experience unique health disparities but have been the subject of limited focused health research [1] . As a consequence of the HIV epidemic, research on transgender health in the USA has focused primarily on HIV/AIDS or has been subsumed in larger studies of 'Lesbian, Gay, Bisexual, Transgender (LGBT) health'. Recent work from the Veterans Health Administration in the USA has focused on health disparities in a large population of transgender veterans [2 & ,3 && ,4 && ,5,6,7 && ]. However, similar work has not been completed in the general American population.
To determine optimal care paradigms, research should address multiple questions regarding mortality and morbidity in transgender individuals. Specifically, little is known regarding the health of transgender individuals with regard to both common medical and mental health outcomes along with comorbid conditions over the life span. Although hypothesis generating surrogate studies exist, specific consequences of sex-affirming interventions on mortality and morbidity are not known. Finally, patient-centered outcome research, including sexual function and fertility, has not been well studied.
Challenges to transgender medical research in the USA include a diverse ethnic and socioeconomic population, where no single center has a sufficiently large patient base to study the population with statistical rigor. Other barriers include designating appropriate patient-oriented outcomes, handling gendered laboratory reference ranges, and the diversity of training and practice across providers. This study offers an overview of the current state of the science and identifies key gaps and opportunities in transgender health research. A dedicated research infrastructure and funding are needed to support advancement of innovations in study design, recruitment, and long-term community engagement to enhance the scientific rigor and reach of transgender health research.
RESEARCH TO DATE
Decades of both clinical experience and medical research demonstrate that medical interventions for gender dysphoria can be essential to achieving well-being for transgender and sex nonconforming individuals [8] . To date, literature on specific health outcomes for transgender individuals consists of several modest cross-sectional studies, a series of large retrospective studies [ 
Overall mortality/morbidity
A retrospective Veterans Health Administration study involving 5117 veterans with medical records linked to the National Death Index found that the top two causes of mortality among the general US population (cardiovascular and oncological) were not increased in a transgender subgroup [7 && ]. This study did not control for sex-affirming interventions such as hormones or surgery. This sole US study specifically examining mortality did suggest increased overall mortality related to suicide compared with the general population (see Mental Health).
European studies have found increased overall mortality in transgender populations who have undergone both hormone and surgical treatment. These studies not only report increased mortality rates because of suicide but also have found increases related to HIV, coronary artery disease, and substance abuse in comparison to general population, notably among transgender women [10, 11] .
There are no European comparison studies of transgender individuals without hormones or surgery. A large retrospective study in 15 different centers, both US and European, of over 2000 transgender adults treated with hormones with or without surgeries found significant comorbidity at the start of hormone treatment: in particular more than 20% depression among both transgender men and women, HIV in 2.6% of transgender women, and type 2 diabetes mellitus in 3.2% of transgender women [12 & ].
Mental health mortality and morbidity
A US study of suicide-related mortality suggested an increased rate compared with the general population [7 && ]. In addition, in a Veterans Health Administration study, transgender veterans had a more than 20 times higher rate of suicide-related events than the general Veterans Health Administration population [6] . Several studies show increased rates of psychiatric events and conditions among transgender persons overall, including increased rates of suicide, suicide attempts, depression, and anxiety [ ]. Transgender care, including hormone therapy, appears to reduce or at least stabilize these effects [16 && ,17] . A systematic review of lowquality studies showed reduction or stabilization in
KEY POINTS
Current published research in transgender healthcare consists primarily of case reports, retrospective and cross-sectional studies, involving largely European settings.
Although gaps in outcomes relating to transgender medical care are large, the body of literature is increasing, suggestive of increased mortality and depression in transgender individuals not receiving optimal care, and possibly a modest increase in cardiovascular risk related to hormone therapy.
The priorities for transgender medical outcomes research should be to determine health disparities and comorbid health conditions over the life span, along with the effects of sex-affirming interventions on morbidity, mortality, and patient-centered outcomes.
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rates of suicide, depression, and general mood with hormone therapy independent of surgery [18] .
Hematologic disease
Historically, venous thromboembolic disease has been of concern in transgender women undergoing hormone therapy [9 & ,19-21,22 & ]. This risk has been primarily identified in older studies in which the thrombogenic synthetic estrogen, ethinyl estradiol, was used as opposed to estradiol or conjugated estrogens. Hypercoagulable risk factors have been associated with many of the cases of reported venous thromboembolism. Recent studies have reported the risk of venous thromboembolism in transgender women may be substantially lower with the use of transdermal estradiol [22 & ,23,24] . In contrast, transgender men have not been observed to suffer similar thrombogenic complications [19] [20] [21] . There are published data suggesting a small erythropoietic consequence to androgen therapy, the health consequence of which remains to be established [25] .
Cardiovascular disease
Although larger, older retrospective studies are mixed in finding elevated risk of cardiovascular morbidity or mortality, more recent data show excessive mortality and morbidity, most notably among transgender women [26] . Wierckx et al. [20] (n ¼ 214) reported an incidence of myocardial infarction among transgender women on hormone therapy that matched that of nontransgender men controls, but exceeded nontransgender women controls. In the same study, an increase in cerebrovascular disease and transient ischemic attack among transgender women were also observed compared with nontransgender men controls. Wierckx et al. [21] examined 100 transgender men and women and found that 6% of transgender women had cardiovascular health problems after an average of 11.3 years on estrogen therapy. These studies involved a greater proportion of older study participants, smokers, and those with additional cardiac risk factors. Transgender men, notably, did not exhibit any difference in the rate of stroke, transient ischemic attack or myocardial infarction compared with nontransgender men controls in these studies.
Diabetes mellitus
There are no data on the prevalence or incidence of diabetes among the US transgender population overall relative to nontransgender controls. With hormone therapy, transgender women are reported to have increased insulin resistance, increased or neutral fasting glucose, and increased subcutaneous fat. Transgender men are reported to have a slight increase in insulin resistance, a decrease in fasting glucose, and an increase in visceral fat [27 & ,28]. Wierckx et al. [20] reported an increase in type 2 diabetes among both transgender women and men, but notably with most of the diagnoses occurring prior to hormone therapy. A 2-year prospective study of metabolically healthy transgender men (n ¼ 43) and women (n ¼ 79) treated with hormone therapy showed 17.2% developing metabolic syndrome, higher than in the general population, with the highest risk among the 20 patients with parallel psychiatric morbidity [29 & ].
Hypertension
There are mixed reports on blood pressure impact from hormone therapy among transgender men and women. A systematic review and meta-analysis of multiple low-quality studies did not identify significant blood pressure changes [26] . Short-term (6-12 month) prospective studies show no significant change with estrogen plus spironolactone and no or small increase in SBP with testosterone therapy in young, healthy sample populations
However, in one cross-sectional European study, 22% of patients who had been on feminizing hormones and 28% of who had been on testosterone for an average of 10 years had elevated blood pressure or treated hypertension [21] .
Lipids
Short-term (6-12 month) prospective studies of estrogen therapy among transgender women show increases in high-density lipoprotein cholesterol and triglycerides [31 & ], a finding also reported in cross-sectional and retrospective cohort studies [21, 32] . Similar studies of testosterone therapy in transgender men report decreases in high-density lipoprotein cholesterol, increases in triglycerides, and either no change or an increase in low-density 34] . Crosssectional studies, retrospective cohort studies, and a systematic literature review all have similar findings [21, 26, 32, 35] .
Oncological mortality and morbidity
Overall cancer incidence in transgender men and transgender women to date has not been found to differ relative to nontransgender controls [20] . One study using European retrospective data, found the incidence of breast cancer among transgender women on estrogen therapy to be similar to secular trends of male breast cancer, with 4.1 cases/100 000 person-years among 2307 transgender women treated with hormones and genital surgery. Rates were lower relative to secular trends for female breast cancer. Among 795 transgender men treated with hormones and surgery (including mastectomy) there was a breast cancer rate of 5.9 cases/100 000 person-years [36] . A US study of 5135 transgender veterans, which did not examine hormone therapy or surgery, found no difference from the expected breast cancer rate in an age-standardized national sample [4 && ,37] . Both of these studies calculated incidence based on the number of cases detected in a population without systematic screening, raising the possibility of underdetection.
Although there have been multiple case reports of prostate cancer among transgender women [38, 39] , a Dutch retrospective chart review of 2306 orchidectomized transgender women reported an overall incidence of prostate cancer of 0.04%, limited by decreased screening and the young average age of 29.3 at the start of feminizing therapy with hormones and then surgery [40 & ]. Although transgender men have presented with ovarian, uterine and cervical cancers [41, 42] , there is no current evidence to suggest that the rates of these conditions among transgender men are higher than the background rate in nontransgender women [7 && ,20] . However, most transgender men in the European studies have undergone hysterectomy within 5 years of starting hormone therapy, limiting their applicability to settings of prolonged testosterone exposure.
Osteoporosis
Prospective and case-control studies of bone mineral density in transgender men suggest that uninterrupted testosterone therapy maintains or increases bone density [43,44 & ]. Prospective studies in transgender men with oophorectomy suggest that bone mineral density may decrease even with testosterone supplementation; this may be if testosterone use is interrupted or the dose is inadequate [45] . Low bone mass has been reported among transgender women prior to hormonal or surgical intervention, possibly because of reduced rates of physical activity or Vitamin D deficiency in this population [46] . Current studies on feminizing hormone therapy and bone mineral density are mixed and some reports are limited methodologically by their use of a comparison group of nontransgender men rather than nontransgender women. The bone densities may depend on the specific hormone regimen [21] . No long-term studies of fracture risk exist, especially in elderly transgender individuals.
Sexual function
Most transgender health studies on sexual function focus on postsurgical outcomes [47] [48] [49] , with little information on sexual function or satisfaction in individuals without sex-confirming surgeries. This may be a function of the larger number of studies from European centers, where hormone therapy is followed by genital surgeries within a few years. The vast majority of sexuality-related studies in the USA -indeed most National Institutes of Health (NIH)-funded research in the transgender population -is focused on HIV and sexually transmitted infections risk [50 && ], usually in targeted at-risk or convenience samples.
Patient-centered and comparative efficacy studies
There is little research on patient-centered physical outcomes of hormone therapy, such as studies comparing the effects and time course of different hormone regimens with identified objective outcomes, such as breast development. Small prospective studies exist, which examine time to menstrual cessation with testosterone therapy [ 
Other reported morbidity
The literature contains multiple case reports of conditions that are observed in persons undergoing feminizing hormone therapy, including the incidence of meningiomas [56, 57] , benign pituitary tumors and prolactinomas [58] . There are reports of the occurrence of autoimmune conditions with a female predominance, such as systemic lupus erythematosus [59] . However, the data are too limited to make a conclusion. Neuroimaging changes have been reported in transgender men and women both prior to and after hormonal interventions [60, 61] .
Translational research, models of care, and medical outcomes
There is limited evaluation of the translation of research findings into clinical practice, focusing on data collection and electronic health records [62] . Preliminary outcomes research has been done on models of providing appropriate, effective care to transgender populations, and focusing on issues of provider 'gatekeeping' access to transition-related interventions [63] . Research has begun to explore effective clinical venues for care ( LGBT specialty clinics versus general practice) [64 & ], and the role of specialists and primary care providers in care [65] .
DISCUSSION
In summary, few prospective studies of transgender medical outcomes exist, and many of these are of short duration (6-24 months) with small sample sizes. The use of mortality as a primary outcome in many studies limits the utility of these studies to describe the disease burden and health-related quality of life. The study participants are usually young and most studies lack controls or comparison populations. The larger retrospective or cross-sectional studies currently available are, with the exception of the Veterans Health Administration study, derived from European data. The vast majority of European research participants has had mastectomy and/or genital surgeries. In a US survey of 6450 transgender and sex nonconforming participants, only 41% of transgender men had had mastectomy and only 20% had hysterectomy, whereas only 21% of transgender women had orchiectomy and 20% had vaginoplasty [66] . In addition, the ethnic, socioeconomic, and healthcare access demographics of US and European populations differ substantially. Finally, the studies have variable duration of hormone use and follow-up interval along with a relative paucity of transmasculine data and participants over age 55.
Going forward, research in the USA will be challenged by the heterogeneity of healthcare for transgender individuals. The US transgender population is ethnically and geographically diverse. Patients have variable health insurance, with primary and transgender-specific care in assorted clinical settings with a variety of providers. Patients begin gender interventions at differing ages, may go on and off hormone therapy for financial and other reasons, and have often self-medicated with hormones obtained through the Internet or social circles [67,68 & ]. Defining and measuring appropriate medical outcomes involving persons with nonbinary sex identities will present additional challenges.
CONCLUSION
Although the gaps in outcomes relating to transgender medical care are large, the current body of literature is increasing and hypothesis generating. Comparison groups of interest may include nontransgender men and women, other sexual minorities, and aging populations with or without estrogen or testosterone replacement Are there differences in outcomes among the most commonly accepted hormone regimens including the following categories of intervention?
Are there serum hormone levels that predict positive (effectiveness) and negative (safety) outcomes?
Androgen therapy, including differences among routes of administration independent of levels achieved
Estrogen therapies, including differences among types (e.g., estradiol versus conjugated estrogens) and among routes of administration independent of levels achieved Antiandrogens, including inhibitors and agents where the mechanism of their action remains to be well characterized. The emerging priorities for transgender medical and healthcare research are outlined in Tables 1 and 2 .
The broad themes of these research priorities elucidate the health disparities and comorbid health conditions of transgender persons over the life span, independent of gender interventions. Comparison groups of interest include nontransgender men and women overall, other sexual or ethnic minorities, and aging populations -with and without estrogen or testosterone replacement. Transgender communities share some similarities to other communities suffering from minority stress and lack of access to healthcare, but we anticipate critical differences as well. Additionally, we would expect from current research that transgender medical interventionsincluding mental health support, hormone therapy, and surgery -change the outcomes. Studies will need to account for the role of access to knowledgeable care providers, and the role specific provider type, and clinical setting. Laboratory reference intervals for transgender individuals will need to be established in the course of developing accurate clinical research. Studies should develop outcome measures to evaluate nonmortality and surrogates, including a focus on patient-centered effectiveness and optimal models of care. Finally, research efforts should prioritize comprehensive, multicenter studies to close as many of the knowledge gaps in as rigorous a fashion as possible. Table 2 . Priority medical outcomes for transgender medical and healthcare research Specific outcomes of highest concern, based on existing data:
Impact of interventions on gender dysphoria itself
Affective mental health issues: suicide, depression, and anxiety Hematologic issues: venous thromboembolic events (related to estrogen), polycythemia concerns (related to androgens) Cardiovascular/cerebrovascular disease including risk factors such as metabolic syndrome, hyperlipidemia(s), diabetes mellitus Effects on preexisting comorbid conditions Medical areas of priority because of risk predicted from physiology and history, although not currently suggested by literature to date:
Breast neoplasms when exposed to estrogens Breast neoplasms after masculinizing chest surgeries, androgens Endometrial and ovarian neoplasms when exposed to androgens Prolactinoma Prostate neoplasms after estrogen exposure and/or orchiectomy Prospective follow-up study indicating that hormone therapy-induced metabolic syndrome is more pronounced during the first year and is higher in treated individuals with psychiatric problems. 30.
